-
China’s NMPA Considers Breakthrough Designations for Xiangxue and Innostellar’s Therapies
•
Xiangxue Pharmaceutical Co., Ltd (SHE: 300147) and Innostellar Biotherapeutics Co., Ltd have both been noted by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) as potential candidates for breakthrough therapy designations (BTDs). Xiangxue’s TAEST16001, a T-cell receptor TCR affinity-enhanced specific T-cell (TAEST) therapy, and Innostellar’s…
-
Athenex Sells China Subsidiaries to TiHe Capital for USD 19 Million
•
US-based Athenex Inc. (Nasdaq: ATNX) announced an agreement to sell all equity interests in its China-based subsidiaries, primarily involved in active pharmaceutical ingredient (API) manufacturing, to China’s TiHe Capital (Beijing) Co., Ltd for RMB 124.4 million ($19 million). The deal, subject to customary closing conditions, will see Athenex receive ~70%…
